Billiontoone (NASDAQ:BLLN) Sees Large Volume Increase - Here's What Happened

Key Points

• Unusually strong volume: About 938,737 shares traded (a 194% increase from the prior session), with the stock near $76.95 — roughly a 7.9% intraday rise from the $72.12 close.
• The company beat quarterly expectations, reporting EPS of $0.11 vs. $0.04 expected and revenue of $96.05M vs. $85.85M expected, with revenue up 113% year‑over‑year.
• Analysts remain mostly positive — six Buys, three Holds and one Sell — yielding a consensus rating of "Moderate Buy" and a consensus target price of $126.71 despite several recent target cuts.

Billiontoone, Inc. (NASDAQ:BLLN - Get Free Report) saw unusually-strong trading volume on Tuesday . Approximately 938,737 shares changed hands during mid-day trading, an increase of 194% from the previous session's volume of 318,964 shares.The stock last traded at $76.9530 and had previously closed at $72.12.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on BLLN shares. BTIG Research dropped their target price on Billiontoone from $160.00 to $140.00 and set a "buy" rating on the stock in a report on Thursday, March 5th. Guggenheim dropped their target price on Billiontoone from $120.00 to $100.00 and set a "buy" rating on the stock in a report on Monday, March 30th. Weiss Ratings reissued a "sell (d)" rating on shares of Billiontoone in a report on Friday. Wall Street Zen raised Billiontoone from a "hold" rating to a "buy" rating in a report on Saturday, March 7th. Finally, Wells Fargo & Company dropped their target price on Billiontoone from $110.00 to $90.00 and set an "equal weight" rating on the stock in a report on Thursday, March 5th. Six research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $126.71.

Billiontoone Stock Up 7.9%

The company has a fifty day moving average price of $77.44. The stock has a market capitalization of $3.58 billion and a P/E ratio of 370.80. The company has a debt-to-equity ratio of 0.12, a quick ratio of 11.32 and a current ratio of 11.69.

Billiontoone (NASDAQ:BLLN - Get Free Report) last issued its quarterly earnings data on Wednesday, March 4th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.07. The firm had revenue of $96.05 million for the quarter, compared to analysts' expectations of $85.85 million. The firm's revenue for the quarter was up 113.0% compared to the same quarter last year. Equities research analysts forecast that Billiontoone, Inc. will post 0.42 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Billiontoone

A number of hedge funds have recently added to or reduced their stakes in the company. Adams Street Partners LLC acquired a new stake in Billiontoone in the fourth quarter valued at about $140,063,000. Baillie Gifford & Co. acquired a new stake in shares of Billiontoone during the 4th quarter valued at approximately $103,786,000. Price T Rowe Associates Inc. MD acquired a new stake in shares of Billiontoone during the 4th quarter valued at approximately $39,717,000. JPMorgan Chase & Co. acquired a new stake in shares of Billiontoone during the 4th quarter valued at approximately $32,078,000. Finally, Wasatch Advisors LP acquired a new stake in shares of Billiontoone during the 1st quarter valued at approximately $29,179,000.

About Billiontoone

BillionToOne NASDAQ: BLLN is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.